Day One Biopharmaceuticals (DAWN) Equity Ratio (2022 - 2025)
Historic Equity Ratio for Day One Biopharmaceuticals (DAWN) over the last 4 years, with Q3 2025 value amounting to 0.88.
- Day One Biopharmaceuticals' Equity Ratio fell 508.12% to 0.88 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.88, marking a year-over-year decrease of 508.12%. This contributed to the annual value of 0.86 for FY2024, which is 638.78% down from last year.
- Latest data reveals that Day One Biopharmaceuticals reported Equity Ratio of 0.88 as of Q3 2025, which was down 508.12% from 0.89 recorded in Q2 2025.
- In the past 5 years, Day One Biopharmaceuticals' Equity Ratio ranged from a high of 0.97 in Q1 2022 and a low of 0.77 during Q2 2024
- Its 4-year average for Equity Ratio is 0.91, with a median of 0.92 in 2024.
- In the last 5 years, Day One Biopharmaceuticals' Equity Ratio plummeted by 1895.98% in 2024 and then soared by 1591.05% in 2025.
- Day One Biopharmaceuticals' Equity Ratio (Quarter) stood at 0.95 in 2022, then fell by 3.12% to 0.92 in 2023, then dropped by 6.39% to 0.86 in 2024, then increased by 1.73% to 0.88 in 2025.
- Its Equity Ratio stands at 0.88 for Q3 2025, versus 0.89 for Q2 2025 and 0.9 for Q1 2025.